CytoMed Therapeutics Limited - Ordinary Shares (GDTC)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Aug 24, 2026Investment Snapshot
- P/B of 2.29 — trading above book value
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -58.3%
- Revenue growing at 396% annually
CytoMed Therapeutics Limited - Ordinary Shares (GDTC) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $12 million . Key value metrics: P/B ratio 2.29, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
CytoMed Therapeutics Limited - Ordinary Shares — Fundamental Analysis Summary
On financial health, GDTC shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -58.3% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.11.
StockPik's composite Value Score for GDTC is 35/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
GDTC shows revenue growing at 396% year-over-year, with earnings declining at 68%.